Intellia Therapeutics Announced The Acceptance Of An Abstract Featuring Redosing Data From The Phase 1 Study Of NTLA-2001 Has Been Selected For An Oral Presentation At The Peripheral Nerve Society Annual Meeting
Intellia Therapeutics Announced The Acceptance Of An Abstract Featuring Redosing Data From The Phase 1 Study Of NTLA-2001 Has Been Selected For An Oral Presentation At The Peripheral Nerve Society Annual Meeting
intellia therapeutics宣佈，NTLA-2001第一階段研究的再劑量數據的摘要被選爲口頭報告在周圍神經協會年會上發表。
NTLA-2001 is an investigational in vivo CRISPR-based gene editing therapy designed to be a single-dose treatment for transthyretin (ATTR) amyloidosis.
NTLA-2001是一種體內CRISPR基因編輯療法，旨在治療甲狀腺激素轉運蛋白（ATTR）澱粉樣變性病，並設計爲單劑治療。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。